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Summary 
Predicting in vivo drug toxicity from in vitro testing requires modelling those 
processes that are not reproduced in vitro. The most obvious difference between 
the two settings is the lack of integrated absorption, distribution, metabolism, and 
excretion (ADME) that govern target tissue exposure in vivo. For equal input 
doses, the concentrations to which in vitro systems are exposed may not 
correspond to those found in vivo. The partners of the European project 
PREDICT-IV in charge of modelling develop prediction models for ADME 
processes and integrate them into generic physiologically based pharmacokinetic 
(PBPK) models. Examples of simulations of concentration-time profiles for 
diazepam and ciclosporin A, in various human or rat organs and tissues, are 
presented here. In vivo drugs' toxicity will be forecasted by coupling the predicted 
target tissue concentration profiles to dose-response relationships observed in 
vitro. Human variability will be evaluated for each component of the approach. 
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1 Introduction  
It is now recognised that replacing animals by in vitro systems for assessment of 
medium to long-term toxicity of drugs or general chemicals requires an 
integration of pharmacokinetics (Bouvier d'Yvoire, et al., 2007). Predicting in vivo 
drug toxicity from in vitro testing requires modelling the absorption, distribution, 
metabolism, and excretion (ADME) processes that are not reproduced in vitro. 
For equal input doses, the concentrations to which in vitro systems are exposed 
may not correspond to the target tissue exposure experienced in vivo. INERIS, 
Simcyp Limited, the German Cancer Research Centre, Emergentec 
Biodevelopment GmbH, and ECVAM, which constitute the modelling team of the 
European project PREDICT-IV, will integrate prediction models for ADME 
processes into global generic physiologically based pharmacokinetic (PBPK) 
models able to simulate concentration-time profiles in human or rat blood and 
tissues. In vivo drugs' toxicity will be predicted by coupling the predicted target 
tissue concentration profiles to dose-response relationships observed in vitro. 
Human variability will be evaluated for each component of the approach. 
While the establishment of predictive dose-response relationships for 
neurotoxicity, liver and kidney toxicity is a very important part of the project, this 
article focuses on the progress made so far on PBPK modelling by PREDICT-IV. 
PBPK models are increasingly used in drug development and regulatory 
toxicology to predict the kinetics and metabolism of substances in the body 
(Barton, et al., 2007, Bouvier d'Yvoire, et al., 2007, Loizou, et al., 2008). In these 
models, the body is represented by a set compartments corresponding specific 
organs or tissues, and the transfers or transports of drugs are dictated by various 
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physiological flows (blood, bile, pulmonary ventilation, etc) (Bois and Paxman, 
1992). A system of differential equations can be written, with parameters 
representing blood flow rates, organ volumes etc., for which information is 
available in the published scientific literature or may be obtainable in vitro 
(Woodruff and Bois, 1993, Parrott, et al., 2005). Numerical integration of that 
differential system computes the quantity and concentration of the drug 
considered in each compartment, as a function of time and exposure dose. Indeed, 
such a description of the body is approximate, if not rough, but a balance has to be 
found between precision (and therefore complexity) and simplicity (ease of use). 
We will briefly describe the global approach taken by PREDICT-IV to 
integrate experimental evidence for a predictive approach to toxicology. We will 
then describe Simcyp's generic PBPK model and the specific parameter setting 
adopted for ciclosporin A and diazepam in rats and humans. Modelling results for 
those two substances are presented and discussed. 
2 Methods 
2.1 General modelling framework 
Fig. 1 presents graphically the integrated prediction and validation framework of 
PREDICT-IV. In vitro studies will provide the necessary data for the development 
of a set of ADME QSARs and multivariate dose-response models for cellular and 
organ-level effects. Those models will be coupled to a generic PBPK model and 
will provide an in silico pharmacokinetic-pharmacodynamic (PK/PD) tool 
predictive of medium- to long-term toxicity. In order to validate that tool, its 
predictions for plasma and tissue drug levels will be confronted to 
pharmacokinetic data obtained in humans or rats. We do not expect to get enough 
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data relating plasma to pathological effects in humans. Therefore the 
pharmacodynamic component will be validated on the basis of already published 
rat data. We do not expect perfect predictions of pharmacokinetics or toxicity data 
and meta-analysis models will be developed to analyse and correct for the 
discrepancies. 
2.2 Simcyp's generic PBPK models 
The structure of the PBPK model developed by Simcyp for rats and humans is 
shown on Fig. 2. A set of ADME sub-models, able to predict substance-specific 
parameter values for a large range of molecules, is already coupled to this model 
(Howgate, et al., 2006, Jamei, et al., 2009a, Jamei, et al., 2009b, Jamei, et al., 
2009c). Obviously, while the model structure remains the same, parameter values 
and corresponding absorption, distribution, metabolism and excretion (ADME) 
sub-models differ between species. Dosing can be by intra-venous injection (i.v.) 
or per os (p.o.) (the dermal and inhalation routes are also developed for humans). 
The liver and gut are sites of metabolism. Renal excretion takes place in the 
kidney. Solving numerically the corresponding set of differential equations yields 
the time-course of the quantity or concentration of a given drug in any of the 
organs or tissues included in the model. 
2.3 Specific parameters for diazepam in rats 
Simcyp also provides default parameter values for diazepam with its rat model. A 
total in vivo clearance of 20.4 mL/min is reported (Klotz, et al., 1976, Igari, et al., 
1983). To model the extra-hepatic metabolism of diazepam in rats, hepatic 
clearance was set equal to three-quarters of total clearance (CLiv = 0.75  CLtot = 
15.3 mL/min; CLr = 0.25  CLtot = 5.1 mL/min). 
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The intravenous injection of 1.2 mg/kg used by Igari et al. (1983) in their 
experiments on Wistar was simulated. 
2.4 Specific parameters for diazepam in humans 
Diazepam is not part of the default substances provided by Simcyp's human 
model. We used the physico-chemical characteristics specified by Simcyp's rat 
model (molecular weight: 284.7 g/mol; log octanol to water partition coefficient: 
2.9; monoprotic base with a pKa of 3.4). Blood binding parameters where 
obtained from the literature (fraction unbound in plasma, fup: 0.022; blood to 
plasma ratio: 0.58) (Klotz, et al., 1975, Klotz, 1985, Jones and Larsson, 2004). 
Tissue-to-plasma concentration ratios (Kp) were automatically estimated by the 
corresponding ADME model. For in vivo clearance, CLiv, the published value of 
1.596 L/h was used (Klotz, et al., 1975). 
To simulate Klotz et al. (1975) data, a two-minute intravenous infusion of 0.1 
mg/kg diazepam was simulated for a representative healthy volunteer, followed 
up for 72 hr. 
2.5 Specific parameters for ciclosporin A in rats 
Ciclosporin A was not one of the drugs predefined for in Simcyp's rat model. We 
used the physico-chemical properties provided by the Simcyp's human model 
(molecular weight: 1202 g/mol; log octanol to water partition coefficient: 4.3; 
neutral compound). Blood binding parameters where obtained from the literature 
(fraction unbound in plasma, fup: 0.062; fraction unbound in blood, fub: 0.05 for 
intra-venous doses up to 6 mg/kg and 0.094 for doses above) (Kawai, et al., 1998, 
Tanaka, et al., 2000). The tissue-to-plasma concentration ratios (or partition 
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coefficients, Kp) (Tab. 1) were derived by multiplying published tissue-to-blood 
ratios (Tanaka, et al., 2000) by fup / fub.  
In vivo plasma clearance values were derived from Tanaka et al., (2000) by 
multiplying the blood clearance by fup / fub: (CLiv: 0.82 mL/min for an intra-
venous dose of 1.2 mg/kg; 0.94 mL/min for 6 mg/kg; 0.35 mL/min for 30 mg/kg). 
Three experiments on Sprague-Dawley rats with 2-minute intra-venous infusions 
of 1.2 mg/kg, 6 mg/kg and 30 mg/kg ciclosporin A, respectively, were simulated 
(Tanaka, et al., 2000). 
2.6 Specific parameters for ciclosporin A in humans 
Simcyp provides default parameter values for ciclosporin A pharmacokinetics 
in humans. We used the predefined "Healthy volunteers" population. To match the 
characteristics of the population studied by Gupta et al. (1990), the reference body 
mass of the subjects was set to an average of 64 kg, with age ranging from 24 to 
34 years, with 50% males. The duration of the simulated study was 24 hr after an 
oral administration of 10mg/kg of ciclosporin A. A first-order oral absorption 
model was used, with rate constant 0.91 h-1 (Kawai, et al., 1998). 
For extrapolation to a larger population the age range was set from 20 to 70 
years. To study variability, Monte Carlo simulations (Bois, et al., 1990, Bois, et 
al., 1991, Bois and Paxman, 1992, Rostami-Hodjegan and Tucker, 2007) of 100 
subjects were performed. 
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3 Results 
3.1 Diazepam in rats and humans 
A set of simulations was performed to compare the model predictions to actual 
data published on rat and human diazepam pharmacokinetics. Only minimal 
adjustments to the parameter values, has described in the Methods section, were 
made. Fig. 3 shows the results obtained for the rat. Only plasma, brain, liver and 
kidney data (Igari, et al., 1983) and model simulations are shown because these 
are the compartments of primary interest in PREDICT-IV. Similar results are 
obtained in the other tissues. 
Fig. 4 presents similar results in human plasma. The experimental data of Klotz 
et al. (1975) for two healthy volunteers are slightly overestimated, but we have 
not attempted here to account for the heterogeneity of the human population.  
3.2 Ciclosporin A in rats and humans 
Fig. 5 shows the data obtained by Tanaka et al. (2000) in Sprague-Dawley rats 
after intra-venous administrations of 1.2, 6 or 30 mg/kg of ciclosporin. The 
model-predicted time-courses are shown on the same Figure. Here again, no 
specific adjustment was made to "fit" the data, beyond the obvious adaptations 
mentioned in the Methods section. 
For humans, Fig. 6 shows the data of Gupta et al. (1990), obtained after oral 
administration of 10 mg/kg of ciclosporin A to a healthy volunteer, in low fat or 
high fat diet conditions. Monte Carlo simulation of 100 similar subjects (diet not 
considered) were performed, and the average, 5th and 95th percentiles of the 
simulated values are plotted. 
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Fig. 7 illustrates the very purpose of all this modelling exercise: predicting the 
concentration time-course of a substance (here ciclosporin A) in the brain, liver 
and kidney for a varied human population. We simulated 100 healthy subjects, 
aged from 20 to 70 years, taking a daily dose of 10 mg/kg of ciclosporin A for 60 
days. Note that during the first week of treatment, liver exposure is the highest of 
the three, but brain exposure after 60 days is higher than liver or kidney exposure.  
Discussion 
Predicting organ toxicity beyond acute effects is a significant scientific challenge. 
The team of PREDICT-IV is taking an inclusive approach to the problem, 
coupling in vitro testing, in silico ADME, PBPK and dose-response models in an 
integrated predictive tool. An important aspect of the work will be the validation, 
or benchmarking, of the model predictions with a set of about 30 reference drugs, 
known for their neurotoxicity, hepatotoxicity or kidney toxicity. To that effect, 
Simcyp Ltd has already extended its human pharmacokinetic model and 
developed a rat model. The results presented here are indeed limited to only two 
compounds, diazepam and ciclosporin, but give an idea of the quality of the 
predictions obtained with the current model. We will test the approach with whole 
set of reference drugs, and we even expect improvements when additional, more 
precise, ADME properties prediction models will be included. 
We have performed here Monte Carlo simulations to describe inter-individual 
variability only to a limited extent, and only for ciclosporin A. This type of 
simulations will be performed for more diverse populations, potentially more 
susceptible to organ toxicity. Accessing this type of results is difficult for in vitro 
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testing alone, hence the synergy with mathematical modelling, which is one of the 
goals of PREDICT-IV. 
The results presented here go only as far as the prediction of organ exposures 
after medium term repeated administration of a drug. We could have extended our 
simulations to longer times or different doses, but stable values were obtained for 
ciclosporin A after 60 days of dosing and we would have gained no more insight 
with additional follow-up. Obviously this may not be true for other compounds 
and will have to be assessed on a case by case basis. In any case, long term target 
organ exposure is the relevant measure of dose for the prediction of organ toxicity 
after sustained exposure. We have still to couple our PBPK model to dose-
response models for a complete PK/PD approach. The dose-response component 
will also add a time dimension of its own, but the work on correlated multi-
dimensional dose-response models in PREDICT-IV has just begun. 
We are focusing on local organ toxicity, for which the target tissue 
concentration can be considered as the relevant measure of dose. Systemic 
toxicity would be much more of a challenge, combining effects of the dysfunction 
of several organs. However, we are only a step away from being able to describe 
the toxic effects of co-administered substances, since our models have the 
capability to account for at least pharmacokinetic and metabolic interactions 
(Rostami-Hodjegan and Tucker, 2004, Bois, submitted). We are therefore 
confident in our ability to make significant contributions to the 3Rs agenda and to 
predictive clinical and environmental toxicology in the near future. 
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Tables 
Tab. 1: Tissue-to-blood partition coefficients used for ciclosporin A in rats. 
Tissue  Dose (mg/kg)
  
1.2 6 30 
Adipose 8.36 7.77 4.94 
Bone 2.81 3.76 1.08 
Brain 0.01 a 0.30 0.53 
Gut 6.39 6.49 2.55 
Heart 7.29 5.74 2.52 
Kidneys 9.54 12.90 4.42 
Liver 14.63 13.64 5.67 
Lungs 8.85 6.32 5.79 
Muscle 1.22 1.46 0.71 
Skin 5.17 3.04 1.12 
Spleen 9.15 8.64 3.61 
 (a)
 The brain concentration was below the limit of detection in Tanaka et al., 
(2000). 
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Figure legends  
Fig. 1: Graphical representation of the integrated prediction and validation 
framework of PREDICT-IV. 
Left panel: Predictive component of project In vitro studies will provide the 
necessary data for the development of a set of ADME QSARs and multivariate 
dose-response models for cellular and organ-level effects. Those models will be 
coupled to a generic PBPK model for humans and rats and will provide an in 
silico pharmacokinetic-pharmacodynamic (PK/PD) tool predictive of medium- to 
long-term toxicity. Right panel: In order to validate that tool, its predictions for 
plasma and tissue drug levels will be confronted to pharmacokinetic data obtained 
in humans or rats. To relate plasma to pathological effects, the pharmacodynamic 
component will be validated on the basis of published animal (rat) data. 
Fig. 2: Graphical representation of the physiologically based pharmaco-
kinetic (PBPK) model of the human or rat body. 
The model structure is the same for rats and humans, but parameter values and 
corresponding absorption, distribution, metabolism and excretion (ADME) sub-
models differ between species. Dosing can be by intra-venous injection (i.v.) or 
per os (p.o.) (the dermal and inhalation routes are being developed for humans). 
The liver and gut are sites of metabolism. Renal excretion takes place in the 
kidney. Solving numerically the corresponding set of differential equations yields 
the time-course of the quantity or concentration of a given drug in any of the 
organs or tissues included in the model. 
Fig. 3: Model predictions and published data on diazepam pharmacokinetics 
in the rat. 
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The rat PBPK model was run to simulate the intra-venous administration of 1.25 
mg/kg of diazepam to Wistar rats (Igari, et al., 1983). The solid lines represent the 
predicted time-courses. The dots figure the corresponding data (average 
concentrations measured in 3 to 5 rats). 
Fig. 4: Model predictions and published data on diazepam time-course in 
human plasma. 
The human PBPK model (solid line) was run to simulate the intra-venous 
administration of 0.1 mg/kg of diazepam to human healthy volunteers. The data 
correspond to those obtained in two subjects (circles and squares, respectively) by 
(Klotz, et al., 1975). 
Fig. 5: Model predictions and published data on ciclosporin A pharmaco-
kinetics in the rat. 
The rat PBPK model was run to simulate the intra-venous administration of 1.2, 6 
or 30 mg/kg of ciclosporin to Sprague-Dawley rats (Tanaka, et al., 2000). The 
solid lines represent the predicted time-courses. The dots (circles: 30 mg/kg dose; 
squares: 6 mg/kg dose; diamonds: 1.2 mg/kg dose) figure the corresponding data 
(average concentrations measured in 3 rats). 
Fig. 6: Modelled and observed ciclosporin A pharmacokinetics in human 
blood. 
The data of Gupta et al. (1990), obtained after oral administration of 10 mg/kg of 
ciclosporin A to a healthy volunteer, are represented by either circles (low fat diet 
conditions) or square (high fat diet). The thick solid line represents the 
corresponding average model predictions for 100 similar subjects (diet not 
considered). The thin lines indicate the 5th and 95th percentiles of the 100 
simulated values. 
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Fig. 7: Predictions of long-term ciclosporin A pharmacokinetics in humans. 
Time-course of ciclosporin A concentrations predicted in the brain, liver and 
kidney of healthy subjects, aged from 20 to 70 years, and taking a daily dose of 10 
mg/kg of ciclosporin A. The lines represent the average concentrations at any 
time, for 100 simulated subjects. The bars at the right indicate the range (from 5th 
to 95th percentiles) of concentrations found in the organs after 60 days of 
treatment. These are relevant values for the prediction of organ toxicity after 
sustained exposure. 
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Fig. 1: Graphical representation of the integrated prediction and validation 
framework of PREDICT-IV. 
Left panel: Predictive component of project In vitro studies will provide the 
necessary data for the development of a set of ADME QSARs and multivariate 
dose-response models for cellular and organ-level effects. Those models will be 
coupled to a generic PBPK model for humans and rats and will provide an in 
silico pharmacokinetic-pharmacodynamic (PK/PD) tool predictive of medium- to 
long-term toxicity. Right panel: In order to validate that tool, its predictions for 
plasma and tissue drug levels will be confronted to pharmacokinetic data obtained 
in humans or rats. To relate plasma to pathological effects, the pharmacodynamic 
component will be validated on the basis of published animal (rat) data. 
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Fig. 2: Graphical representation of the physiologically based pharmaco-
kinetic (PBPK) model of the human or rat body. 
The model structure is the same for rats and humans, but parameter values and 
corresponding absorption, distribution, metabolism and excretion (ADME) sub-
models differ between species. Dosing can be by intra-venous injection (i.v.) or 
per os (p.o.) (the dermal and inhalation routes are being developed for humans). 
The liver and gut are sites of metabolism. Renal excretion takes place in the 
kidney. Solving numerically the corresponding set of differential equations yields 
the time-course of the quantity or concentration of a given drug in any of the 
organs or tissues included in the model. 
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Fig. 3: Model predictions and published data on diazepam pharmacokinetics 
in the rat. 
The rat PBPK model was run to simulate the intra-venous administration of 1.25 
mg/kg of diazepam to Wistar rats (Igari, et al., 1983). The solid lines represent the 
predicted time-courses. The dots figure the corresponding data (average 
concentrations measured in 3 to 5 rats). 
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Fig. 4: Model predictions and published data on diazepam time-course in 
human plasma. 
The human PBPK model (solid line) was run to simulate the intra-venous 
administration of 0.1 mg/kg of diazepam to human healthy volunteers. The data 
correspond to those obtained in two subjects (circles and squares, respectively) by 
(Klotz, et al., 1975). 
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Fig. 5: Model predictions and published data on ciclosporin A pharmaco-
kinetics in the rat. 
The rat PBPK model was run to simulate the intra-venous administration of 1.2, 6 
or 30 mg/kg of ciclosporin to Sprague-Dawley rats (Tanaka, et al., 2000). The 
solid lines represent the predicted time-courses. The dots (circles: 30 mg/kg dose; 
squares: 6 mg/kg dose; diamonds: 1.2 mg/kg dose) figure the corresponding data 
(average concentrations measured in 3 rats). 
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Fig. 6: Modelled and observed ciclosporin A pharmacokinetics in human 
blood. 
The data of Gupta et al. (1990), obtained after oral administration of 10 mg/kg of 
ciclosporin A to a healthy volunteer, are represented by either circles (low fat diet 
conditions) or square (high fat diet). The thick solid line represents the 
corresponding average model predictions for 100 similar subjects (diet not 
considered). The thin lines indicate the 5th and 95th percentiles of the 100 
simulated values. 
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Fig. 7: Predictions of long-term ciclosporin A pharmacokinetics in humans. 
Time-course of ciclosporin A concentrations predicted in the brain, liver and 
kidney of healthy subjects, aged from 20 to 70 years, and taking a daily dose of 10 
mg/kg of ciclosporin A. The lines represent the average concentrations at any 
time, for 100 simulated subjects. The bars at the right indicate the range (from 5th 
to 95th percentiles) of concentrations found in the organs after 60 days of 
treatment. These are relevant values for the prediction of organ toxicity after 
sustained exposure. 
 
